Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats

Pathology Research and Practice

Volumn 212, Issue 4, 2016, Pages 247-251

  Song, Shilei ^a   Nie, Qingmei ^a   Li, Zhifang ^a   Du, Gang ^b  

^a WEIFANG PEOPLE'S HOSPITAL   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Neuroprotection; Parkinson's disease; Substantia nigra

Indexed keywords

ACETYLCHOLINE; CURCUMIN; DOPAMINE; FIBROBLAST GROWTH FACTOR 2; GLUTATHIONE PEROXIDASE; HEAT SHOCK PROTEIN 70; MALONALDEHYDE; NERVE GROWTH FACTOR; OXIDOPAMINE; PROTEIN TYROSINE KINASE A; SUPEROXIDE DISMUTASE; ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; LOCOMOTION; MALE; MORRIS WATER MAZE TEST; NERVOUS SYSTEM FUNCTION; NEUROFUNCTION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; ROTAROD TEST; SPATIAL LEARNING; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PARKINSONISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CURCUMIN; DISEASE MODELS, ANIMAL; MALE; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84959088176     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2015.11.012     Document Type: Article

References (30)

1. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
2. Ilango A., Kesner A.J., Keller K.L., Stuber G.D., Bonci A., Ikemoto S. Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. J. Neurosci. 2014, 34:817-822.
3. Licker V., Turck N., Kövari E., Burkhardt K., Côte M., Surini-Demiri M., Lobrinus J.A., Sanchez J.C., Burkhard P.R. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics 2014, 14:784-794.
4. Freestone P.S., Guatteo E., Piscitelli F., di Marzo V., Lipski J., Mercuri N.B. Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the substantia nigra pars compacta. Neuropharmacology 2014, 79:467-775.
5. Li R., Liang T., Xu L., Zheng N., Zhang K., Duan X. Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ARE signaling pathway. Brain Res. 2013, 1523:1-9.
6. Li R., Liang T., Li Y., Jiang W., Huang R. Effects of l-dopa methyl ester on visual cortex injury induced by amblyopia and its underlying mechanism. Neurosci. Lett. 2012, 508:95-100.
7. La Rosa L.R., Matrone C., Ferraina C., Panico M.B., Piccirilli S., Di Certo M.G., Strimpakos G., Mercuri N.B., Calissano P., D'Amelio M., Nisticò R. Age-related changes of hippocampal synaptic plasticity in AβPP-null mice are restored by NGF through p75NTR. J. Alzheimers Dis. 2013, 33:265-272.
8. Harrington A.W., St Hillaire C., Zweifel L.S., Glebova N.O., Philippidou P., Halegoua S., Ginty D.D. Recruitment of actin modifiers to TrkA endosomes governs retrograde NGF signaling and survival. Cell 2011, 146:421-434.
9. Xiong N., Yang H., Liu L., Xiong J., Zhang Z., Zhang X., Jia M., Huang J., Zhang Z., Mohamed A.A., Lin Z., Wang T. bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease. Environ. Toxicol. Pharmacol. 2013, 36:411-422.
10. Yang F., Liu Y., Tu J., Wan J., Zhang J., Wu B., Chen S., Zhou J., Mu Y., Wang L. Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF. Nat. Commun. 2014, 5:5627.
11. Hui J.S., Murdock G.A., Chung J.S., Lew M.F. Behavioral changes as side effects of medication treatment for Parkinson's disease. Adv. Neurol. 2005, 96:114-129.
12. Li Y., Zhang T. Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett. 2014, 346:197-205.
13. Wongcharoen W., Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 2009, 133:145-151.
14. Yang J., Song S., Li J., Liang T. Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson's disease rat. Pathol. Res. Pract. 2014, 210:357-362.
15. Li R., Zheng N., Liang T., He Q., Xu L. Puerarin attenuates neuronal degeneration and blocks oxidative stress to elicit a neuroprotective effect on substantia nigra injury in 6-OHDA-lesioned rats. Brain Res. 2013, 1517:28-35.
16. Alves C.J., de Santana L.P., dos Santos A.J., de Oliveira G.P., Duobles T., Scorisa J.M., Martins R.S., Maximino J.R., Chadi G. Early motor and electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis and gender differences on clinical outcome. Brain Res. 2011, 1394:90-104.
17. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
18. Prinz M., Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 2014, 15:300-312.
19. Wang J., Yu J.T., Wang H.F., Meng X.F., Wang C., Tan C.C., Tan L. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2015, 86:101-109.
20. Rodriguez M., Morales I., Rodriguez-Sabate C., Sanchez A., Castro R., Brito J.M., Sabate M. The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging. Front. Neuroanat. 2014, 8:80. 7.
21. Gunn D.G., Naismith S.L., Bolitho S.J., Lewis S.J. Actigraphically-defined sleep disturbance in Parkinson's disease is associated with differential aspects of cognitive functioning. J. Clin. Neurosci. 2014, 21:1112-1115.
22. Bové J., Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
23. Simola N., Morelli M., Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 2007, 11:151-167.
24. Fan X., Zhang C., Liu D.B., Yan J., Liang H.P. The clinical applications of curcumin: current state and the future. Curr. Pharm. Des. 2013, 19:2011-2031.
25. Pohanka M. Alzheimer's disease and oxidative stress: a review. Curr. Med. Chem. 2013, 21(3):356-364.
26. Liu Y., Zhang L., Liang J. Activation of the Nrf2 defense pathway contributes to neuroprotective effects of phloretin on oxidative stress injury after cerebral ischemia/reperfusion in rats. J. Neurol. Sci. 2015, 351:88-92.
27. Montjean D., Ménézo Y., Benkhalifa M., Cohen M., Belloc S., Cohen-Bacrie P., de Mouzon J. Malonaldehyde formation and DNA fragmentation: two independent sperm decays linked to reactive oxygen species. Zygote 2010, 18(3):265-268.
28. Das B., Modi G., Dutta A. Dopamine d3 agonists in the treatment of Parkinson's disease. Curr. Top. Med. Chem. 2015, 15:908-926.
29. Bosboom J.L., Stoffers D., Wolters E.Ch. The role of acetylcholine and dopamine in dementia and psychosis in Parkinson's disease. J. Neural. Transm. Suppl. 2003, 65:185-195.
30. Oksala N.K., Ekmekçi F.G., Ozsoy E., Kirankaya S., Kokkola T., Emecen G., Lappalainen J., Kaarniranta K., Atalay M. Natural thermal adaptation increases heat shock protein levels and decreases oxidative stress. Redox Biol. 2014, 3:25-28.